by Dr. Paul Karpecki | Sep 27, 2019 | Practice Pearls
A patented in-office procedure plus at-home care gives patients relief from this common condition Blepharitis is one of the most common eye conditions, and yet it is one of the most under-diagnosed. Why? First, like dry eye or allergies, blepharitis symptoms can be...
by Dr. Paul Karpecki | May 31, 2019 | Practice Pearls
Making glaucoma medications easier and more affordable Eyecare practitioners have several options for the drugs we prescribe to patients. First and generally most expensive, there are the branded, proprietary, patented drugs such as Xiidra, Rocklatan, and Vyzulta....
by Dr. Paul Karpecki | Apr 19, 2019 | Practice Pearls
A drug for acute NAION is currently in phase III clinical trials After glaucoma, the second-most common source of optic nerve damage is Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). We usually describe this to a patient as a “stroke in the eye,” where...
by Dr. Paul Karpecki | Mar 22, 2019 | Practice Pearls, Technology & the Internet
It’s safe, more affordable than ever, and useful for numerous indications If there is one compelling example of the value of ultrasound technology in eye care, it’s an experience I had this past year. I was conducting a retina workshop at the Review of Optometry New...
by Dr. Paul Karpecki | Jan 11, 2019 | Practice Pearls
In 2019, we have access to two exciting new therapies This past year brought some significant advances in eye care as far as new tests, technology, and drug approvals, and 2019 is looking just as promising. In 2018, we gained access to the first two new glaucoma drugs...
